NHL
Haematology · 2014–2014
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| rituximab Treatment of CD20 positive B-cell non-Hodgkin's lymphoma (NHL), including previously untreated diffuse large B-cell NHL and follicular NHL, in combination with… | Nov 2014 | Recommended | none received |
What the PBS pays
$24M in government benefit over 2024–25, across 57,210 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| rituximab | $23.9M |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| mitozantroneMITOZANTRONE EBEWE mitozantrone (as hydrochloride) 10mg/5mL solution f | 2001 | 6 |
| epirubicinEPIRUBICIN ACCORD epirubicin hydrochloride 10mg/5mL concentrated injec | 1992 | 5 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.